THRX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 118422 min ago

@ $4.06

Wydano: 12 vas. 2024 @ 23:00

Zwrot: 0.12%

Live Chart Being Loaded With Signals

Commentary (13 vas. 2024 @ 22:59):

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients...

Stats
Dzisiejszy wolumen	677 694
Średni wolumen	849 600
Kapitalizacja rynkowa	181.50M
EPS	$0 ( 2024-03-14 )
Następna data zysków	( $0 ) 2024-05-11
Last Dividend	$0.250 ( 2015-09-08 )
Next Dividend	$0 ( N/A )
P/E	-3.03
ATR14	$0.0670 (1.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-14	Yi Kathy	Sell	3 250	Restricted Stock Units
2024-02-14	Yi Kathy	Sell	99 634	Stock Option (Right to Buy)
2024-02-14	Stein Steven H	Sell	3 250	Restricted Stock Units
2024-02-14	Orbimed Advisors Llc	Sell	650 600	Common Stock
2024-02-14	Hayden Donald J Jr	Sell	10 000	Common Stock

INSIDER POWER
-13.00
Last 94 transactions
Buy: 24 821 782 \| Sell: 19 785 944

Wolumen Korelacja

Długi: 0.04 (neutral)

Krótki: 0.00 (neutral)

Signal:(59.853) Neutral

Theseus Pharmaceuticals, Korelacja

10 Najbardziej pozytywne korelacje
OPNT	0.971
DVCR	0.964
AMYT	0.959
AVEO	0.959
ITMR	0.949
NVCN	0.946
MSVB	0.941
FLXS	0.94
FTIV	0.938
ASML	0.937

10 Najbardziej negatywne korelacje
KBNT	-0.964
IRBT	-0.962
SIFY	-0.949
AGFY	-0.949
CSSEN	-0.949
GOVX	-0.947
ENNV	-0.946
AHPI	-0.944
SGML	-0.941
CSSEP	-0.941

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Theseus Pharmaceuticals, Korelacja - Waluta/Towar

0.55
( weak )

0.71
( moderate )

-0.35
( neutral )

0.43
( neutral )

-0.51
( weak negative )

-0.64
( weak negative )

Theseus Pharmaceuticals, Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$-438 000 (0.00 %)
EPS:	$-1.220

FY	2022
Przychody:	$0
Zysk brutto:	$-438 000 (0.00 %)
EPS:	$-1.220

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.84

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.010

Financial Reports:

No articles found.

Theseus Pharmaceuticals, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Theseus Pharmaceuticals, Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.250	2014-08-26
Last Dividend	$0.250	2015-09-08
Next Dividend	$0	N/A
Payout Date	2015-09-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	1.55	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

1.55

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.238	1.200	-7.94	-9.52	[0 - 0.3]
returnOnEquityTTM	-0.245	1.500	-3.83	-5.75	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	29.93	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	29.29	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	6.70	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0156	-1.500	9.74	-10.00	[0 - 0.6]
interestCoverageTTM	88.35	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.133	2.00	-0.378	-0.755	[0 - 30]
freeCashFlowPerShareTTM	-1.134	2.00	-0.567	-1.134	[0 - 20]
debtEquityRatioTTM	0.0163	-1.500	9.93	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-13.58	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.984

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.19	1.000	-0.423	0	[1 - 100]
returnOnEquityTTM	-0.245	2.50	-2.46	-5.75	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.134	2.00	-0.378	-1.134	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.133	2.00	-0.378	-0.755	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.060

Theseus Pharmaceuticals,

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.